Dirozalkib

Dirozalkib
Identifiers
  • 5-Chloro-2-N-(6-methyl-5-piperidin-4-yl-2,3-dihydro-1,4-benzodioxin-8-yl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC27H32ClN5O4S
Molar mass558.09 g·mol−1
3D model (JSmol)
  • CC1=CC(=C2C(=C1C3CCNCC3)OCCO2)NC4=NC=C(C(=N4)NC5=CC=CC=C5S(=O)(=O)C(C)C)Cl
  • InChI=1S/C27H32ClN5O4S/c1-16(2)38(34,35)22-7-5-4-6-20(22)31-26-19(28)15-30-27(33-26)32-21-14-17(3)23(18-8-10-29-11-9-18)25-24(21)36-12-13-37-25/h4-7,14-16,18,29H,8-13H2,1-3H3,(H2,30,31,32,33)
  • Key:ABKQZNVWMCRCGQ-UHFFFAOYSA-N

Dirozalkib is a drug that was developed by Xuanzhu Biopharmaceutical for the treatment of non-small cell lung cancer. It is an anaplastic lymphoma kinase inhibitor.

It was approved for use in China in August of 2025.

References

  1. ↑ "Dirozalkib". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
  2. ↑ Ai X, Guo R, Zhang L, Fang J, Zhang Y, Chen J, et al. (February 2026). "Preclinical characterization and first-in-human, phase I trial of the novel ALK inhibitor dirozalkib in advanced non-small cell lung cancer". European Journal of Cancer. 235 116221. Oxford. doi:10.1016/j.ejca.2026.116221. PMID 41539180.
  3. ↑ Fang L, Jiang X, Song K, Shi P, Wang L, Xu L, et al. (December 2025). "Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib)". Cancer Chemotherapy and Pharmacology. 95 (1): 122. doi:10.1007/s00280-025-04837-x. PMID 41348226.
  4. ↑ Basmajian K, Stepanyan Z, Sarkissian S (July 2026). "A Systematic Review and Meta-analysis of Clinical Trials in ALK-positive Non-small Cell Lung Cancer". Anticancer Research. 46 (7): 3609–3618. doi:10.21873/anticanres.18227. PMID 42373241.
  5. ↑ S&P Capital IQ (22 August 2025). "The Innovative Drug Dirozalkib Tablets Independently Developed by Xuanzhu Biopharm Obtained Drug Registration Approval from NMPA". MarketScreener.